ADVANCE trial

Encapsulated hemoglobin has been studied for more than 50 years without progressing to advanced trials in humans. Its immediate outlook is not, therefore, very promising. Nonetheless, because the encapsulated hemoglobin is potentially so similar to a natural red blood cell, some specialists believe it holds the best long-term hope for the production of artificial blood. 

The efficacy of telaprevir was assessed in multiple clinical studies. Among the Phase 111 studies, the ADVANCE trial evaluated treatment-naive patients, and the REALIZE trial evaluated treatment-experienced patients. In addition to improving SVR rate, the telaprevir program aimed to minimize overall treatment duration. Because PR therapy is associated with a number of significant adverse events, a shortened overall dosing plan would provide significant benefit to patients."... 

In the ADVANCE trial, the effect of treatment duration was assessed via the following three-arm trial design ... 

Hydrazine sulfate [10034-93-2] N2H4 H2SO4, originally advanced by the Syracuse Cancer Research Institute for treatment of cancerous cachexia and tumor inhibition (221), now has Investigational New Dmg (IND) status in the United States. Clinical evaluations are under way at various institutions such as Harbor-UCLA Medical Center (222) and the Mayo Clinic. After extensive trials, hydrazine sulfate has been approved as an anticancer dmg in Russia (223). Chemical stmctures for estabUshed dmgs in the United States may be found in Reference 224. 

At the in vivo assay level, the classic ip-ip (iateraperitoneal) in vivo model has been replaced as a selection criteria for advancement of new dmg candidates to clinical trial. More stringent alternative models iaclude subcutaneous or subrenal capsule implantation of tumor followed by iatravenous dmg dosiag (7) and the human tumor xenograft models ia aude mice (8). 

These potential sampling problems must be solved in advance of the unit test. The conclusions drawn from any unit test are strongly affected by the accuracy of the sampling methods and the resultant analyses. Methods should be discussed and practiced before the actual unit test. Analysts should use the trial measurements in prehm-inary plant-performance analysis to ensure that the results will be use-bil during the actual unit test. 

The majority of promising drug candidates emerging from marine natural products research to date are potential cancer treatments. Six anti-cancer compounds that are either marine natural products or synthetic analogs of marine natural products have made it to clinical trials. The first of these compounds to enter clinical trials was didemnin B (43), one of a family of cyclic depsipetides isolated from the Caribbean tunicate Trididemnum solidum Didemnin B was advanced to Phase II clinical trials for treatment of small cell lung cancer, myeloma, prostate cancer, and melanoma. Unfortunately, no favorable responses were found so the compound has been withdrawn. Crude extracts of another Caribbean tunicate, Ecteinascidia turbinata, showed extremely... 

Selective AR agonists are undergoing clinical trials for cardiac arrhythmias and pain (Ai) cardiac imaging and inflammation (A2a) colon cancer, rheumatoid arthritis, psoriasis, and dry eye (A3). Selective AR antagonists are either in or advancing toward clinical trials for kidney disorders (Ax) Parkinson s disease (A2a) diabetes and asthma (A2B) cancer and glaucoma (A3). 

Interference with specific cell-cell and cell-matrix adhesion mechanisms is another rapidly advancing approach to therapeutically interfere with angiogenesis. Antagonistic antibodies (Vitaxin) to the integrin heterodimer av 33 have been shown to act on the blood vessels of tumors but not on the resting organ vasculature. Vitaxin demonstrated some promise in Phase II clinical trials. 

Systematic screening experiments have identified more than 100 synthetic compounds with potent antiangiogenic activity. The mode of action for most of these molecules is not well understood, but some of the 40 compounds are well advanced in clinical trials (Table 3). The first substance to have entered clinical trials was the Fumagillin-derivative AGM 1470. Fumagillin is an antibiotic which inhibits bFGF- and PDGF-induced endothelial cell proliferation. The mechanism of action of AGM 1470 is poorly understood, but it was shown that it binds and inhibits the metalloprotease methionine aminopeptidase (MetAp-2). 

In the aitways, inhibition of PDE4 is much more antiinflammatory than bronchodilatory. Although effective in animal experiments, the neuronal and gastric side effects of PDE4-inhibitors have so far impeded their use in humans. Two new orally active PDE4-inhibitors (roflumilast, cilomilast) have shown some effectiveness in advanced clinical trials, but have not yet been approved. 

The follow-up for subjects withdrawn from investigational product treatment/trial treatment. Should be decided in advance. 

---